You need to be logged in to see the full monograph.

USE OF ACITRETIN/ETRETINATE IN PREGNANCY

Date of issue: October 2026, Version: 4

CLINICAL SUMMARY
Teratogenicity/Fetotoxicity
Human teratogen. Only prescribed to women who have agreed to a pregnancy prevention programme (PPP).

Evidence-base
Quantity: limited (~155 exposed pregnancies). Quality: moderate – based on case reports. There are additional data on related compounds that are known teratogens.
 

Benefit-risk
There is no clinical situation where the benefit of using acitretin during pregnancy will outweigh the fetal risk.
 

Clinical recommendations
• Women of childbearing potential should agree to a pregnancy prevention programme (PPP) before being prescribed acitretin.
• Pregnancy should be avoided for three years following cessation of treatment.
• Women taking acitretin should be made aware that concurrent alcohol consumption could significantly increase acitretin’s elimination half-life.
• Women who conceive during treatment or within three years of cessation should be counselled about potential teratogenicity and those who choose to continue their pregnancy should be offered an earlier anomaly scan, which may not detect all anomalies associated with retinoid exposure.

DETAILED SUMMARY: Oral retinoids and their metabolites are associated with a significant teratogenic risk and should only be prescribed and dispensed to women under a Pregnancy Prevention Programme (PPP).

Acitretin (a metabolite of etretinate) is a second-generation oral retinoid licensed for the treatment of severe psoriasis, palmoplantar pustular psoriasis, congenital ichthyosis, and keratosis follicularis (Darier’s disease). The elimination half-life of acitretin is ~96 hours. However, concurrent exposure to alcohol may induce reverse metabolism to etretinate, which is stored in the liver and has a much longer elimination half-life. Effective contraception (ideally two complementary forms) is therefore recommended from four weeks prior to commencing treatment with acitretin, until three years after treatment cessation.

Multiple malformations, including facial dysmorphia, cleft palate, cardiovascular malformations, and limb and skeletal defects have been reported following in utero exposure to acitretin. The available data are limited to approximately 155 exposed pregnancies, and the absolute risk of malformation is unquantified, partly due to a high rate of elective termination of pregnancy following exposure. Experience from other retinoids suggests that risk following acitretin exposure is likely to be significant.

An increased risk of miscarriage has been observed following in utero exposure to isotretinoin and exposure to acitretin may carry similar risks. There are also case reports of impaired neurodevelopment in the absence of malformation following retinoid exposure.

Guidelines advise that women should avoid pregnancy for three years after acitretin treatment. If conception occurs within three years of exposure, anomaly scans carried out by a fetal medicine specialist could be offered from 16 weeks gestation.

Other risk factors may also be present in individual cases which may independently increase the risk of adverse pregnancy outcome. Clinicians are reminded of the importance of consideration of such factors when performing case-specific risk assessments.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from UKTIS.org to ensure you are using the most up-to-date version.